Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy

Lipids in Health and Disease

Volumn 15, Issue 1, 2016, Pages

  Tada, Hayato ^a   Kobayashi, Junji ^b   Kawashiri, Masa Aki ^a   Miyashita, Kazuya ^c   Nohara, Atsushi ^a   Inazu, Akihiro ^a   Nakajima, Katsuyuki ^d   Mabuchi, Hiroshi ^a   Yamagishi, Masakazu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c Immuno Biological Laboratories Co Ltd   (Japan)

^d GUNMA UNIVERSITY   (Japan)

Author keywords

Endothelial lipase; Familial hypercholesterolemia; Lipoprotein lipase

Indexed keywords

COLESTILAN; ENDOTHELIAL LIPASE; ESTERASE; EZETIMIBE; GLYCOSYLATED HEMOGLOBIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; ROSUVASTATIN; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; EPICHLOROHYDRIN; HYPOCHOLESTEROLEMIC AGENT; IMIDAZOLE DERIVATIVE; LIPG PROTEIN, HUMAN; LPL PROTEIN, HUMAN; RESIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD STORAGE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; EVENING DOSAGE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; HUMAN; JAPANESE (PEOPLE); MALE; MIDDLE AGED; MORNING DOSAGE; PLASMA; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMBINATION DRUG THERAPY; ENZYMOLOGY; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; DRUG THERAPY, COMBINATION; EPICHLOROHYDRIN; EZETIMIBE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; IMIDAZOLES; LIPASE; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; RECEPTORS, LDL; RESINS, SYNTHETIC; ROSUVASTATIN CALCIUM;

EID: 84962439628     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-016-0238-z     Document Type: Article

References (21)

1. Nilsson-Ehle P, Garfinkel AS, Schotz MC. Lipolytic enzymes and plasma lipoprotein metabolism. Annu Rev Biochem. 1980;49:667-93.
2. Hitsumoto T, Ohsawa H, Uchi T, Noike H, Kanai M, Yoshinuma M, et al. Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis. 2000;153:391-6.
3. Hitsumoto T, Yoshinaga K, Aoyagi K, Sakurai T, Kanai M, Uchi T, et al. Association between preheparin serum lipoprotein lipase mass and acute myocardial infarction in Japanese men. J Atheroscler Thromb. 2002;9:163-9.
4. Totsuka M, Miyashita Y, Ito Y, Watanabe H, Murano T, Shirai K. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Atherosclerosis. 2000;153:175-9.
5. Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, Watanabe H, et al. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract. 1999;46:35-41.
6. Endo K, Miyashita Y, Saiki A, Oyama T, Koide N, Ozaki H, et al. Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. J Atheroscler Thromb. 2004;11:341-7.
7. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J, Peloso GM, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22-31.
8. Do R, Stitziel NO, Won HH, Jørgensen AB, Duga S, Angelica Merlini P, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015;518:102-6.
9. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-67.
10. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-99.
11. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380:572-80.
12. Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345-52.
13. Gidding SS, Ann Champagne M, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. The agenda for familial hypercholesterolemia: A scientific statement from the American Heart Association. Circulation. 2015;132:2167-92.
14. Kawashiri MA, Nohara A, Noguchi T, Tada H, Nakanishi C, Mori M, et al. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia. Am J Cardiol. 2012;109:364-9.
15. Shirakawa T, Nakajima K, Shimomura Y, Kobayashi J, Stanhope K, Havel P, et al. Comparison of the effect of post-heparin and pre-heparin lipoprotein lipase and hepatic triglyceride lipase on remnant lipoprotein metabolism. Clin Chim Acta. 2015;440:193-200.
16. Shirakawa T, Nakajima K, Yatsuzuka S, Shimomura Y, Kobayashi J, Machida T, et al. The role of circulating lipoprotein lipase and adiponectin on the particle size of remnant lipoproteins in patients with diabetes mellitus and metabolic syndrome. Clin Chim Acta. 2015;440:123-32.
17. Ishida T, Miyashita K, Shimizu M, Kinoshita N, Mori K, Sun L, et al. ELISA system for human endothelial lipase. Clin Chem. 2012;58:1656-64.
18. Tada H, Kawashiri MA, Takata M, Matsunami K, Imamura A, Matsuyama M, et al. Infantile cases of sitosterolaemia with novel mutations in the ABCG5 gene: extreme hypercholesterolaemia is exacerbated by breastfeeding. JIMD Rep. 2015;21:115-22.
19. Tada H, Kawashiri MA, Tanaka A, Nakano T, Nakajima K, Inoue T, et al. Post-prandial remnant lipoprotein metabolism in autosomal recessive hypercholesterolaemia. Eur J Clin Invest. 2012;42:1094-9.
20. CARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45:25-33.
21. Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65:2267-75.